<?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/header.php");
?>
    <div class="content">
	
        <section id="home-page-banner" class="home-page-banner">
            
                
            
		<div class="row">
		     <img src="assets/images/banner1.jpg" alt="" class="img-responsive home-banner" style="">
                     
                  </div> 
                
            
            
    </section>
        <div class="container" style="    margin-top: -90px;
    padding-bottom: 54px;">
                <div class="row">
                    <div class="col-md-6">
                        <div class="button-allign-left" style="    padding: 0px 0px 0px 177px;">
                        <a href=""><button type="button" class="btn btn-danger discover" style="
           border-radius: 50px;
    font-size: 16px;
    border-color: #fff;
    background-color: #fff;
    font-color: black;
    background: transparent;
    font-family: Acuminbold;
    padding: 10px;">DISCOVER THE DIFFERENCE</button></a>
                    </div>
                    </div>
                      <div class="col-md-6">
                          <div class="button-allign-right" style="    padding: 0px 0px 0px 100px;
">
                        <a href=""><button type="button" class="btn btn-danger explore" style="
        
    
     border-radius: 50px;
    font-size: 16px;
    border-color: #fff;
    background-color: #fff;
    font-color: black;
    background: transparent;
    font-family: Acuminbold;
    padding: 10px;">EXPLORE COVERAGE</button></a>
                          </div>
                    </div>
                </div>
            </div>
	<style type="text/css" media="screen">
        


button.btn.btn-danger.mybutton {
    outline: none;
}

.whiteback {
    background-image: url(images/diffrenciation/1.png);
    
    
    background-repeat: no-repeat;

}
    </style>
		 <section id="our-services" class="our-services" style="margin-top:-7px;">
                <div class="container">
                    <div class="row">
					  <div class="col-xs-12 col-sm-3 col-md-2 col-lg-2 col-xl-2">
					  </div>
                        <div class="col-xs-12 col-sm-6 col-md-10 col-lg-10 col-xl-10">
                            <div class="top-text">
                                <h3 class="mission">
								
                                    ON A MISSION TO SAVE MILLIONS AT RISK </h3>
                                <h4 class="tetraphase">Tetraphase is committed to making novel antibiotics accessible <br>to all patients in need.</h4>
                               <a href="https://www.tphase.com/contact-us" target="_blank"><h5 class="developments"><br><br><br><b>SEE OUR LATEST DEVELOPMENTS ></b> </h5></a>
                            </div>
                        </div>
						 <div class="col-xs-12 col-sm-3 col-md-2 col-lg-2 col-xl-2">
					  </div>
                    </div>
                
                </div>
            </section>
        <!--banner ends -->
     <section id="our-department" class="our-department">
                <div class="container">
               
                    <div class="row">
                        <div class="">
                         
                            <div class="tab-content tab-content col-sm-12 col-md-12  col-lg-12 col-xl-12 no-padding">
                                <div class="tab-pane active" id="CARDIOLOGY">
                                    <div class="tab-image">
                                        
                                    <p class="" style="font-size:16px;">
                                       cIAI, complicated intra-abdominal infection.   </p>
									   <p style="font-size:14px;font-family:AcuminPro"><b>References: 1.</b> XERAVA [prescribing information]. Watertown, MA: Tetraphase Pharmaceuticals, Inc.; 2018. <b>2.</b> Zhanel GG, Cheung D, Adam H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. <i>Drugs.</i> 2016;76:567-588.</p><br><br><br><br>
									   
									   <p class="blue">
                                       Indications and Usage </p>
                                
                                    <p class="italic">XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: <i>Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium<br> Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in<br> patients</i> 18 years or older.</p><br>
									<p><u>Limitations of Use</u></p>
									<p>
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).</p><br>
<p class="blue">Usage</p>
<p class="">To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should <br>be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data,<br> local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p><br>
<p class="blue">Important Safety Information</p>
<p>XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. <br>Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.</p><br>
<p>The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. </p><br>
<p>The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.</p><br>
<p><i>Clostridium difficile </i>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, and may range in severity from <br>mild diarrhea to fatal colitis. </p><br>
<p>The most common adverse reactions observed in clinical trials (incidence â‰¥ 3%) were infusion site reactions (7.7%), nausea (6.5%), and <br>vomiting (3.7%). </p><br>
<p>XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti-anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA.  Discontinue XERAVA if any of these adverse reactions are suspected.</p><br>
<p><b>To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</b></p> 
                                </div>
                           
                          
                            </div>
                        </div>
                        <!-- tab content -->
                    </div>
                </div>
            </section>
    </div>
	<style>
	@media only screen and (max-width: 1920px) {
    .mybutton {position: relative;
    top: 794px;
    font-size: 16px;
    margin-left: 395px;
    border-color: #fff;
    background-color: #fff;
    font-color: black;
    background: transparent;
    font-family: Acuminbold; }}
	</style>
	
   <?php
	// $pageTitle = "Page Title";
	// $description = "Description text here";
	// $keywords = "Keywords here";
	// $activePage = "home";
	
	include("includes/footer.php");
?>